Continuous measurement of heart rate variability following carbon dioxide pneumoperitoneum during nitrous oxide/sevoflurane anaesthesia

Background: Previous studies of autonomic nervous system activity through analysis of heart rate variability (HRV) have demonstrated increased sympathetic activity during positive-pressure pneumoperitoneum. We employed an online, continuous method for rapid HRV analysis (MemCalc™, Tarawa, Suwa Trust, Tokyo, Japan) to demonstrate rapid changes in autonomic nervous system during pneumoperitoneum for laparoscopy. Method: The powers of low-frequency (LF) (0.04-0.15 Hz) and high-frequency (HF) (0.15-0.4 Hz) components of HRV in 20 healthy adult patients were monitored under sevoflurane anaesthesia for 10 minutes after the initiation of carbon dioxide pneumoperitoneum at 10 mmHg. Results: Heart rate increased promptly, but transiently, just after peritoneal insufflation. At that time, the ratio between the LF and HF components increased on HRV. Similar, but small, changes occurred following head-up positioning. Conclusion: By monitoring HRV continuously, we have demonstrated that the change in autonomic nervous system balance induced by peritoneal insufflation was prompt and transient. The change in autonomic nervous system activity could have been due to increased sympathetic activity, reduced vagal activity, or both.Keywords: heart rate variability; positive pressure pneumoperitoneum; continuous monitorin

Observation of the decay mode K_L -> pi^+ pi^- e^+ e^-

We report on results of an experimental search for the K_L -> pi^+ pi^- e^+ e^- decay mode. We found 13.5 +- 4.0 events and determined its branching ratio to be (4.4 +- 1.3(stat) +- 0.5(syst))*10^{-7}. The result agrees well with the theoretical prediction.Comment: 9 pages, 6 eps-figures, LaTeX2e, graphicx package, submitted to Physics Letters

Experimental search for the decay mode K_L -> pi^0 gamma e^+ e^-

We report on results of a search for the decay mode K_L -> pi^0 gamma e^+ e^- conducted by the E162 experiment at KEK. We observed no events and set a 90% confidence level upper limit of Br(K_L -> pi^0 gamma e^+ e^-)< 7.1x10^{-7} for its branching ratio. This is the first published experimental result on this decay mode.Comment: 10 pages, 4 figures, submitted to Physics Letters

Installation and Test of the ATLAS Muon Endcap Trigger Chamber Electronics

For the detector commissioning planned in 2007, a sector assembly of the ATLAS muon endcap trigger chambers is being progressed in CERN. Final technical test of the electronics mounted on a sector must be made at this stage. For systematic test of the electronics (sector test), we have developed a DAQ system on top of the ATLAS online software framework. The system is not dedicated only for this test, but can be used also for the front-end detector part of the overall ATLAS DAQ system. In the presentation, the procedure, meaning and results of the sector test are discussed after brief introduction of the TGC electronics and the sector structure as a construction unit. We introduce plans of further detailed and elaborated tests for the whole system using cosmic ray and single halo muons when all the TGC sub-detector part is completed as concluding remark

Measurement of tau polarization in e+ e- annihilation at sqrt{s}=58 GeV

The polarization of tau leptons in the reaction e+ e- --> tau+ tau- has been measured using a e+e- collider, TRISTAN, at the center-of-mass energy of 58 GeV. From the kinematical distributions of daughter particles in tau --> e nu nu-bar, mu nu nu-bar, rho nu or pi(K) nu decays, the average polarization of tau- and its forward-backward asymmetry have been evaluated to be 0.012 +- 0.058 and 0.029 +- 0.057, respectively.Comment: 18 pages, 5 figure

HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer

Background: HAGE protein is a known immunogenic cancer-specific antigen. Methods: The biological, prognostic and predictive values of HAGE expression was studied using immunohistochemistry in three cohorts of patients with BC (n=2147): early primary (EP-BC; n=1676); primary oestrogen receptor-negative (PER-BC; n=275) treated with adjuvant anthracycline-combination therapies (Adjuvant-ACT); and primary locally advanced disease (PLA-BC) who received neo-adjuvant anthracycline-combination therapies (Neo-adjuvant-ACT; n=196). The relationship between HAGE expression and the tumour-infiltrating lymphocytes (TILs) in matched prechemotherapy and postchemotherapy samples were investigated. Results: Eight percent of patients with EP-BC exhibited high HAGE expression (HAGEþ) and was associated with aggressive clinico-pathological features (Ps<0.01). Furthermore, HAGEþexpression was associated with poor prognosis in both univariate and multivariate analysis (Ps<0.001). Patients with HAGE+ did not benefit from hormonal therapy in high-risk ER-positive disease. HAGE+ and TILs were found to be independent predictors for pathological complete response to neoadjuvant-ACT; P<0.001. A statistically significant loss of HAGE expression following neoadjuvant-ACT was found (P=0.000001), and progression-free survival was worse in those patients who had HAGE+ residual disease (P=0.0003). Conclusions: This is the first report to show HAGE to be a potential prognostic marker and a predictor of response to ACT in patients with BC